GE Healthcare Technologies Inc (GEHC) AI Stock Analysis

• Market Cap: $38.25B
• Dividend Yield: 0.17%
• Average Volume (3M): 3.86M
• Price to Earnings (P/E): 17.4
• Beta (1Y): 1.27
• Revenue Growth: 3.52%
• EPS Growth: 32.21%
• Country: US
• Employees: 53,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 1.07
• Shares Outstanding: 455,521,600
• 10 Day Avg. Volume: 3,333,582
• 30 Day Avg. Volume: 3,860,061
• PEG Ratio: 0.41
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 1.81
• P/FCF Ratio: 23.00
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 2.04
• Enterprise Value/Gross Profit: 4.99
• Enterprise Value/Ebitda: 10.86
• 1Y Price Target: $89.08
• Price Target Upside: 6.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): 4.55
• Revenue Forecast (FY): $20.54B

• Rating: 74 Outperform
• Price Target: $84.00 ▲(0.05% Upside)

GE Healthcare Technologies Inc. demonstrates strong financial performance and a positive outlook from the latest earnings call, despite facing cash flow challenges and tariff impacts. The technical indicators suggest a neutral trend, while the valuation appears fair. The company's strategic initiatives and raised guidance contribute positively to the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Strategic Partnerships

Strategic partnerships enhance product offerings and market reach, fostering innovation and sustained revenue streams.

Cash Generation

Strong cash generation supports financial stability and investment in growth opportunities, ensuring long-term viability.

Negative Factors

Tariff Impacts

Tariff impacts can erode profit margins, affecting financial performance and competitiveness over the long term.

Patient Care Solutions Challenges

Challenges in key segments can hinder overall growth and require strategic adjustments to regain momentum.

Decline in Free Cash Flow

A decline in free cash flow may indicate inefficiencies in cash management, impacting future investment capacity and financial health.

GE Healthcare Technologies Inc Business Overview & Revenue Model

Company Description

GE Healthcare Technologies Inc (GEHC) is a leading global provider of medical technologies and digital solutions, serving healthcare providers around the world. The company operates in various sectors, including imaging, monitoring, biomanufacturing, and digital solutions. GEHC's core products encompass advanced imaging systems such as MRI and CT scanners, ultrasound machines, and patient monitoring devices, as well as software solutions that enhance operational efficiency and patient care in healthcare facilities.

How the Company Makes Money

GE Healthcare generates revenue through several key streams, primarily from the sale of medical imaging equipment, monitoring devices, and software solutions. The company also earns income from service contracts related to the maintenance and support of its products, as well as consumables and accessories that accompany its medical devices. Additionally, GEHC has established significant partnerships with healthcare providers, research institutions, and technology firms, which contribute to its revenue through collaborative projects and the development of innovative healthcare solutions. The ongoing demand for advanced medical technologies, particularly in emerging markets and during healthcare transformations, also plays a crucial role in driving GEHC's earnings.

GE Healthcare Technologies Inc Financial Statement Overview

Summary

GE Healthcare Technologies Inc. shows strong revenue growth and profitability with significant improvements in leverage and return on equity. However, challenges in cash flow generation could impact liquidity, necessitating a focus on cost management and cash flow improvement.

Income Statement

GE Healthcare Technologies Inc. demonstrates strong revenue growth with a TTM increase of 1.4%, indicating a positive trajectory. The company maintains healthy profitability with a gross profit margin of 40.8% and a net profit margin of 10.9% in the TTM. EBIT and EBITDA margins are also robust at 15.9% and 18.8% respectively, reflecting efficient operations. However, the slight decline in gross profit margin from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet shows a significant improvement in leverage, with a TTM debt-to-equity ratio of 0.20, down from 1.11 the previous year, indicating reduced financial risk. The return on equity remains strong at 23.7%, showcasing effective use of equity. However, the equity ratio is not explicitly calculated, and the decrease in stockholders' equity over the years could be a concern for long-term stability.

Cash Flow

Cash flow analysis reveals challenges with a significant decline in free cash flow growth by 70.4% in the TTM, indicating potential liquidity issues. The operating cash flow to net income ratio is low at 0.09, suggesting that cash generation from operations is not keeping pace with net income. However, the free cash flow to net income ratio remains healthy at 50.7%, indicating some level of cash flow efficiency.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	20.25B	19.67B	19.55B	18.34B	17.59B	17.16B
Gross Profit	8.26B	8.21B	7.92B	7.18B	7.17B	6.77B
EBITDA	3.80B	3.67B	3.51B	3.17B	3.54B	3.41B
Net Income	2.22B	1.99B	1.57B	1.92B	2.25B	13.85B
Balance Sheet
Total Assets	36.13B	33.09B	32.45B	27.54B	26.31B	24.23B
Cash, Cash Equivalents and Short-Term Investments	4.00B	2.89B	2.50B	1.45B	556.00M	1.01B
Total Debt	10.74B	9.38B	9.86B	8.63B	437.00M	468.00M
Total Liabilities	25.91B	24.44B	25.14B	17.95B	9.41B	9.25B
Stockholders Equity	9.99B	8.45B	7.13B	9.36B	16.66B	14.73B
Cash Flow
Free Cash Flow	463.00M	1.55B	1.71B	1.80B	1.36B	1.43B
Operating Cash Flow	913.00M	1.95B	2.10B	2.11B	1.61B	1.69B
Investing Cash Flow	-1.02B	-914.00M	-558.00M	-398.00M	-1.76B	19.99B
Financing Cash Flow	-367.00M	-573.00M	-478.00M	-822.00M	-263.00M	-21.54B

GE Healthcare Technologies Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GEHC, the sentiment is Positive. The current price of 83.96 is above the 20-day moving average (MA) of 79.44, above the 50-day MA of 76.73, and above the 200-day MA of 74.50, indicating a bullish trend. The MACD of 2.59 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 81.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GEHC.

GE Healthcare Technologies Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HQY	76 Outperform	$8.27B	44.36	9.01%	―	12.20%	98.75%
GEHC	74 Outperform	$38.25B	17.36	24.22%	0.17%	3.52%	32.21%
DOCS	72 Outperform	$8.26B	34.98	24.61%	―	20.21%	44.14%
HNGE	70 Outperform	$3.91B	-9.05	―	―	50.67%	-578.00%
VEEV	66 Neutral	$36.70B	43.38	13.72%	―	15.96%	27.91%
TEM	52 Neutral	$12.56B	-59.66	-72.61%	―	72.58%	76.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GE Healthcare Technologies Inc Corporate Events

GE Healthcare Announces $1.25 Billion Notes Offering

On December 1, 2025, GE Healthcare Technologies Inc. announced the commencement and pricing of an underwritten offering of $1.25 billion in aggregate principal amount of notes, with $600 million due in 2028 and $650 million due in 2035. This financial move, involving major underwriters like Goldman Sachs and BNP Paribas, is expected to impact the company’s financial strategy and market positioning, with the notes anticipated to be issued around December 15, 2025, pending customary closing conditions.